Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30729563 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL29245844 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL3525995 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL5314317 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL2634064 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL3470472 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL924412 | 0.87 | PPM1D (0.34) | PPM1D | |
| SCHEMBL4725652 | 0.87 | BDKRB2 (0.34) | PPM1D | |
| SCHEMBL28580288 | 0.87 | PPM1D (0.34) | PPM1D | |
| SCHEMBL4416435 | 0.86 | PPM1D (0.33) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230121086-A1 | RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11518772-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20210380604-A1 | TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| EP-3853233-A1 | TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | Nikang Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2250171-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | Achaogen, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7659279-B2 | 2-{(2S)-2-[({4-[3-Chloro-4-fluoroanilino]-7-methoxyquinazolin-5-yl}oxy)methyl]pyrrolidin-1-yl}-2-oxoethanol; epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; breast, colorectal and head and neck cancer | ASTRAZENECA AB (SE) | 2010-02-09 | — | — | US | disclosed |
| WO-2009137130-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2008028662-A1 | N-[1-(3-AMINO-4-PHENYL-BUTYRYL)-4-HYDROXY-PYRROLIDIN-2-YLMETHYL}-PROPIONAMIDE AND RELATED COMPOUNDS AS DPP-IV INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | WO | disclosed |
| EP-1622620-B1 | QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
| EP-1622620-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096226-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | PPM1D 40/4885NR1H2 2154/4885 |
| US-20210380604-A1 | TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPN2 | PPM1D 49/4885NR1H2 1466/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PPM1D 367/4885NR1H2 1539/4885 |
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | EGFR, ERBB2, ERBB4 | PPM1D 675/4885NR1H2 1756/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | PPM1D 528/4885NR1H2 2872/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | PPM1D 2603/4885NR1H2 2769/4885 |
| US-20230121086-A1 | RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | PPM1D 3164/4885NR1H2 5/4885 |
| US-11518772-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | PPM1D 40/4885NR1H2 2154/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PPM1D 367/4885NR1H2 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.